The development of industrial partnerships is an essential vector for the transfer of research results and technologies developed in the lab, by providing tailor-made solutions to industrials in the sectors concerned, in terms of know-how and cutting-edge technologies. Legal and IP considerations are supported by the DR6 CNRS (“Service Partenariat et Valorisation -SPV) or the TTO SAYENS.
Interaction with the socio-economic world can take several forms:
- Research collaboration projects, in particular by mobilizing appropriate funding (regional, national or European).
- A services offering, in particular through our technology platforms and transfer unit
- Specific partnership agreements to bring new chemical compounds to market

ZOOM ON ONGOING COLLABORATIVE RESEARCH PROGRAMS
NEXTFOODPACK : a “France 2030” project bringing together more than 20 public/private players to develop the food packaging solutions of the future
COMPANY: Wipack, Air liquide, Lactips, Ahlstorm (France)

KEYWORDS: Chemical safety, Microbiological safety, Recycling, Multi-criteria approach
ADEPT: AI for cardiovascular surgery: towards the development of a digital twin to facilitate patient monitoring
COMPANY: CASIS (Dijon), ENNOIA (Besançon)

KEYWORDS: AI, digital twins, aortic dissection, 4D MRI
COMETE PROJECT : a regional partnership in the field of radiotherapeutics for the treatment of colorectal and digestive cancers.
COMPANY: ONCODESIGN PRECISION MEDECINE (Dijon)

KEYWORDS : nuclear imaging, chelating agents, radiopharmaceuticals, oncology
The ‘CIFRE’ funding instrument is used to support the design of new chelating agents for alpha- therapy
COMPANY: CHEMATECH (Dijon)

KEYWORDS : chelating agents, Molecular targeted radioTherapy, alpha-emitters
Design of new multivalent radiopharmaceuticals: launch of a solid partnership with ambitious goals
COMPANY: RADIOMUNE PHARMA (Marseille)

KEYWORDS: Molecular targeted radiotherapy, ADC, bioconjugation, theranostic approach.
ANR PRCE Nose To Brain : An innovative solution to target the brain’s tumour cells
COMPANY: CERES BRAIN THERAPEUTICS (Paris)

KEYWORDS: radiotherapy, glioblastoma, nasal injection, formulation